Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Mitochondrial Pathways, Permeability Transition Pore, and Redox Signaling in Cardioprotection: Therapeutic Implications

Open access
Penna, Claudia, Perrelli, Maria-Giulia, Pagliaro, Pasquale·2013·Antioxidants & Redox Signaling

Abstract

Reperfusion therapy is the indispensable treatment of acute myocardial infarction (AMI) and must be applied as soon as possible to attenuate the ischemic insult. However, reperfusion is responsible for additional myocardial damage likely involving opening of the mitochondrial permeability transition pore (mPTP). A great part of reperfusion injury occurs during the first minute of reperfusion. The prolonged opening of mPTP is considered one of the endpoints of the cascade to myocardial damage, causing loss of cardiomyocyte function and viability. Opening of mPTP and the consequent oxidative stress due to reactive oxygen and nitrogen species (ROS/RNS) are considered among the major mechanisms of mitochondrial and myocardial dysfunction. Kinases and mitochondrial components constitute an intricate network of signaling molecules and mitochondrial proteins, which interact in response to stressors. Cardioprotective pathways are activated by stimuli such as preconditioning and postconditioning (PostC), obtained with brief intermittent ischemia or with pharmacological agents, which drastically reduce the lethal ischemia/reperfusion injury. The protective pathways converging on mitochondria may preserve their function. Protection involves kinases, adenosine triphosphate-dependent potassium channels, ROS signaling, and the mPTP modulation. Some clinical studies using ischemic PostC during angioplasty support its protective effects, and an interesting alternative is pharmacological PostC. In fact, the mPTP desensitizer, cyclosporine A, has been shown to induce appreciable protections in AMI patients. Several factors and comorbidities that might interfere with cardioprotective signaling are considered. Hence, treatments adapted to the characteristics of the patient (i.e., phenotype oriented) might be feasible in the future. Antioxid. Redox Signal. 18, 556–599. I. Introduction A. Acute myocardial infarction and reperfusion injury B. Strategies to reduce injury II. Mitochondrial Network A. Important kinases of mitochondrial network involved in I/R injury and cardioprotection 1. GSK-3β in cell survival 2. PKC family in the I/R scenario and cardioprotection 3. The role of STAT-3 in cardioprotection by PreC and PostC 4. Pim-1 kinase in the I/R scenario and cardioprotection 5. Bcl-2 family: interaction with mitochondria 6. AMP-activated protein kinase, a metabolic regulator in health and disease B. Important components of mitochondria in the network involved in I/R and cardioprotection 1. Mitochondrial permeability transition pore 2. Putative mitochondrial ATP-sensitive potassium channels 3. Mitochondrial Cx43 4. Mitochondrial uncoupling proteins C. ROS/RNS: from mitochondria to activation of kinases of the network III. Role of Mitochondria in Acute I/R Injury A. mPTP opening in acute I/R 1. Consequences of prolonged mPTP opening B. Prevention of prolonged mPTP opening C. Transient opening of mPTP can be protective D. Chronic ischemia and mitochondria IV. Cardioprotective Strategies Targeting Mitochondria in Acute I/R Injury A. PreC and PostC B. Redox signaling and acidosis in early reperfusion 1. Detrimental effects of excessive ROS 2. Beneficial effects of redox signaling and acidosis V. Timing and Targets of ROS Signaling in Cardioprotection A. ROS/RNS signaling may be modulated by antioxidants B. Role of SNO in regulating mitochondrial function in I/R and cardioprotection VI. Preservation of Functional and Morphological Integrity of Mitochondria by PostC VII. Summary of PreC and PostC Pathways United at Reperfusion VIII. The Second Window of Protection IX. Autophagy and Mitophagy X. Comorbidities, I/R, and Cardioprotection A. Mitochondria and MS 1. Cardioprotection in MS B. Cardioprotection in Aging C. Cardioprotection in hypertension and hypertrophy XI. Transition to the Clinical Setting A. The possible reasons of variable outcomes with ischemic PostC B. Pharmacological PostC C. Features of a successful cardioprotective approach in early reperfusion XII. Executive Summary and Conclusions

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/ars.2011.4459

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 179

Metadata

Authors
Penna, C., Perrelli, M.-G., & Pagliaro, P.
Venue
Antioxidants & Redox Signaling
Published
2013-02-10
Volume
18
Issue
5
Pages
556-599
ISSN
  • 1523-0864 (ISSN-L)
  • 1557-7716
OpenAlex
W1965224599
Cited by
179
References
48
FWCI
11.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.